37
Participants
Start Date
May 31, 2012
Primary Completion Date
July 31, 2013
Study Completion Date
July 31, 2014
BIBF 1120
200 mg BID oral for 28 day cycle
Cleveland Clinic, Cleveland
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
University of Virginia, Charlottesville
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
Wake Forest University Health Sciences
OTHER
University of Virginia
OTHER
Massachusetts General Hospital
OTHER
The Cleveland Clinic
OTHER
Patrick Y. Wen, MD
OTHER